Resmed Stock Price, News & Analysis

Resmed (NYSE: RMD) reported strong Q4 2025 results with significant growth across key metrics. Revenue increased 10% to $1.3 billion, while operating profit grew 19% to $454.5 million. The company achieved notable improvements in gross margin, expanding 230 basis points to 60.8%.

For the full fiscal year 2025, Resmed delivered revenue of $5.1 billion, up 10%, with diluted earnings per share of $9.51. The company generated robust operating cash flow of $1.8 billion. The board approved a 13% increase in quarterly dividend to $0.60 per share. Additionally, Resmed announced the acquisition of VirtuOx, strengthening its position in at-home diagnostic services for sleep and respiratory conditions.

Resmed (NYSE: RMD, ASX: RMD) has scheduled its fourth quarter fiscal 2025 earnings release for Thursday, July 31, 2025, after the NYSE market close. The company will host a webcast to discuss the results at 1:30 p.m. PDT / 4:30 p.m. EDT on the same day.

The earnings webcast will be accessible through Resmed's investor relations website at investor.resmed.com. A replay will be available approximately two hours after the webcast, along with a phone replay accessible from July 31 to August 14, 2025, using the conference ID 13754703.

Resmed (NYSE: RMD, ASX: RMD) has been named the Official Sleep Partner of the Qatar Airways British & Irish Lions Tour to Australia 2025. The company will launch 'Tackle Your Sleep,' a digital campaign featuring rugby legends to raise awareness about sleep health. The six-week tour will include 10 matches across Australia, with an estimated 40,000 fans attending.

The partnership highlights the critical role of sleep in athletic performance, as research shows that half of rugby and cricket players are classified as poor sleepers. According to Resmed's 2025 Global Sleep Survey, one in four people globally choose to live with poor sleep, despite its negative impacts on mental health, physical performance, and daily activities.

Resmed (NYSE: RMD) has acquired VirtuOx, a leading independent diagnostic testing facility for sleep, respiratory, and cardiac conditions. VirtuOx's virtual testing platform provides at-home diagnostic services, helping reduce barriers to diagnosis with fast, flexible, and affordable options. The acquisition aims to streamline the diagnostic process, accelerate time between evaluation and treatment, and expand access to care for patients with sleep-disordered breathing and related conditions.

VirtuOx will operate as a fully owned subsidiary of Resmed, maintaining its existing brand and leadership team. The acquisition strengthens Resmed's virtual care capabilities, enhances its digital ecosystem, and deepens relationships with healthcare providers. Financial terms were not disclosed as the acquisition is not considered material to Resmed's financial results.

ResMed (NYSE: RMD) reported strong Q3 fiscal 2025 results with revenue growing 8% to $1.3 billion and operating profit up 14% to $426.3 million. The company achieved a gross margin improvement of 140 basis points to 59.3% and generated operating cash flow of $579 million.

Key financial metrics include diluted earnings per share of $2.48 and non-GAAP diluted earnings per share of $2.37. Revenue growth was driven by increased demand for sleep devices and masks portfolio, with U.S., Canada, and Latin America growing 9%, while Europe, Asia, and other markets grew 8% on a constant currency basis.

During the quarter, ResMed paid $78 million in dividends and repurchased 314,000 shares for $75 million. The board declared a quarterly dividend of $0.53 per share, payable on June 12, 2025.

Resmed (NYSE: RMD, ASX: RMD), the global leader in health technology, has appointed Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. Reporting to CEO Mick Farrell, Schwartz brings over 20 decades of finance experience from health tech and financial services sectors.

Schwartz joins from Illumina, where she served as Head of Investor Relations, managing shareholder engagement, corporate strategy, and financial performance communications. Her previous roles include Head of IR and Treasurer at MSCI, managing over $2 billion in investments and $4 billion in debt, and various leadership positions at Moody's and Citigroup.

This appointment aligns with Resmed's 2030 strategy to drive shareholder value and empower 500 million people worldwide to achieve their full health potential through better sleep and breathing health solutions.

Resmed (NYSE: RMD) has announced the nationwide U.S. availability of NightOwl™, an FDA-cleared home sleep apnea test. The device is a fingertip sensor designed to diagnose obstructive sleep apnea (OSA) from home, addressing a critical healthcare gap where 80% of OSA cases remain undiagnosed.

The disposable device can record up to 10 nights of sleep data per patient, utilizing peripheral arterial tonometry technology to measure blood flow changes, oxygen saturation, and pulse rate. Key features include auto-scored results, integration with Resmed's Somnoware, and pairing with the myAir™ app for user guidance.

NightOwl's clinical validation through a multicenter study demonstrated close agreement with expert-scored sleep lab testing PSG in measuring sleep apnea severity. The technology aims to simplify the diagnostic process for both healthcare providers and patients, supporting timely diagnosis and treatment of OSA, which affects nearly one billion people globally.

Resmed (NYSE: RMD, ASX: RMD) has announced it will release its third quarter fiscal 2025 financial and operational results on Wednesday, April 23, 2025, after the NYSE market close. The company will host a webcast to discuss the results at 1:30 p.m. PDT / 4:30 p.m. EDT on the same day.

The earnings webcast will be accessible through the investor relations section of Resmed's website. A replay will be available approximately two hours after the webcast, with a phone replay option available until May 7, 2025. Resmed, operating in 140 countries, specializes in AI-powered digital health solutions, cloud-connected devices, and intelligent software for home healthcare, focusing on sleep and breathing care.

Resmed (NYSE: RMD) announced groundbreaking research published in The Lancet Respiratory Medicine showing that CPAP therapy significantly reduces mortality risk in sleep apnea patients. The largest-ever meta-analysis, analyzing over 1 million patients across 30 studies, revealed that CPAP users have a 37% lower risk of all-cause mortality and a 55% lower risk of cardiovascular-related death compared to non-users.

The study demonstrates a dose-response relationship, indicating greater survival benefits with more consistent CPAP use. This research included data from 10 randomized controlled trials and 20 real-world evidence studies, with an average follow-up period of nearly five years.

The findings are particularly significant given that obstructive sleep apnea (OSA) affects over one billion people worldwide, with more than 80% of cases remaining undiagnosed and untreated. The study establishes CPAP therapy as a life-saving intervention that requires only air, without drugs or surgery.